Jean-Marie Cuillerot - 11 Jan 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRV	Stock Option (Right to Buy)	Award	$0	+99,300		$0.000000	99,300	11 Jan 2024	Common Stock	99,300	$4.82	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Twenty-five percent (25%) of the shares subject to the option shall vest on February 1, 2025, and the remaining shares subject to the option shall vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.